Allos seeks re-evaluation of EMA CHMP opinion on FOLOTYN for PTCL Allos Therapeutics.

Allos seeks re-evaluation of EMA CHMP opinion on FOLOTYN for PTCL Allos Therapeutics, Inc . PTCL comprises a biologically diverse group of aggressive, rare blood cancers which have a worse prognosis than almost every other types of lymphoma, including B-cell lymphoma. Regarding to current CHMP guidelines, a final opinion on the re-examination could possibly be issued by the EMA within four to five a few months. KlegermanScalable creation of gene therapy vectors: an interview with Frank UbagsSome antibiotics could make MRSA more harmful We believe FOLOTYN has the potential to present an important new treatment option for sufferers with relapsed or refractory peripheral T-cell lymphoma, a sign that there are no EMA-approved therapies and no accepted regular of care currently, said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics.

Among the season’s list of casualties are 750 jobs at the Dayton La-Z-Boy reducing and sewing facility which is being relocated to Mexico, and another 400 from the closure of La-Z-Boy’s Tremonton, Utah plant. Meanwhile, 350 workers will watch the bulk of their careers at the Whirlpool plant in Cleveland also become siphoned off to Mexico. The President of La-Z-Boy openly cites the reason for the relocation at La-Z-Boy as the lower cost framework inherent in a Mexican-based operation. Following closure of its Utah service, La-Z-Boy’s upholstery division will have 5.5 million sq. Feet of upholstery manufacturing space in North America including 4 still.8 million still left in the U.S. And 700,000 founded in Mexico. Once this stage of the La-Z-Boy relocation of manufacturing operations is completed, the company expects to realize more than $25 million in annual cost benefits by 2011.